- Hem
- Om universitetet
- Hitta person
- Marcus Borenäs
Marcus Borenäs
Doktorand/projektassistent
Avd för medicinsk kemi och cellbiologi-
Novel signaling and treatment regimes in Anaplastic Lymphoma Kinase driven neuroblastoma
models
Marcus Borenäs
2024 -
Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell
growth
Wei-Yun Lai, Tzu-Po Chuang, Marcus Borenäs, Dan E. Lind, Bengt Hallberg, Ruth H. Palmer
CELL DEATH AND DIFFERENTIATION - 2024 -
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR
inhibition
Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, Wei-Yun Lai, Jikui Guan, Joel Johansson, Eva Jennische, Alexander Schmidt, Yeshwant Kurhe, Jonatan L. Gabre, Agata Aniszewska, Anneli Strömberg, Mats Bemark, Michael N. Hall, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer
Proceedings of the National Academy of Sciences of the United States of America - 2024 -
IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling
Pathway.
Jikui Guan, Marcus Borenäs, Junfeng Xiong, Wei-Yun Lai, Ruth H. Palmer, Bengt Hallberg
Cancers - 2023 -
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK
mutation.
Marcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, Dan E. Lind, Barbara Witek, Jikui Guan, Patricia Mendoza-García, Tafheem Masudi, Arne Claeys, Tzu-Po Chuang, Abeer El Wakil, Badrul Arefin, Susanne Fransson, Jan Koster, Mathias Johansson, Jennie Gaarder, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer
The EMBO journal - 2021 -
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUG alpha) in neuroblastoma patient samples with chromosome arm 2p
rearrangements
Niloufar Javanmardi, Susanne Fransson, Anna Djos, Ganesh Umapathy, Malin Östensson, J. Milosevic, Marcus Borenäs, Bengt Hallberg, P. Kogner, Tommy Martinsson, Ruth H. Palmer
Genes Chromosomes & Cancer - 2020 -
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma
Cells
Muhammad Wasi Alam, Marcus Borenäs, Dan E. Lind, Diana Lizeth Cervantes-Madrid, Ganesh Umapathy, Ruth H. Palmer, Bengt Hallberg
Frontiers in Oncology - 2019 -
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma
cells.
Diana Lizeth Cervantes-Madrid, Joanna Szydzik, Marcus Borenäs, Mats Bemark, Jean Cui, Ruth H. Palmer, Bengt Hallberg
Scientific reports - 2019